Mohamed Shelan1, Lukas Anschuetz2, Adrian D Schubert2, Beat Bojaxhiu1, Alan Dal Pra1, Frank Behrensmeier1,3, Daniel M Aebersold1, Roland Giger2, Olgun Elicin4. 1. Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 4, 3010, Bern, Switzerland. 2. Department of Otorhinolaryngology - Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. 3. Radiation-Oncology-Centre, Biel - Seeland - Berner Jura, Biel, Switzerland. 4. Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 4, 3010, Bern, Switzerland. olgun.elicin@insel.ch.
Abstract
BACKGROUND: The optimal treatment strategy for stage I-II glottic squamous cell carcinoma (SCC) is not well-defined. This study analyzed treatment results and prognostic factors. PATIENTS AND METHODS: This is a single-institution retrospective analysis of 244 patients with T1-2 glottic SCC who underwent normofractionated radiotherapy (RT) and/or surgery between 1990 and 2013. The primary endpoint was relapse-free survival (RFS). RESULTS: Median age was 65 years (range: 36-92 years), the majority (82%) having stage I disease. Definitive RT was used in 82% (median dose: 68 Gy, 2 Gy per fraction). Median follow-up was 59 months. The 5‑year RFS rates were 83 and 75% (p = 0.05) for stage I and 62 and 50% (p = 0.47) for stage II in the RT and surgery groups, respectively. Multivariate analyses indicate T1 vs. T2 and RT vs. surgery as independent prognostic factors for RFS, with hazard ratios of 0.38 (95% confidence interval, CI: 0.21-0.72) and 0.53 (95% CI: 0.30-0.99), respectively (p < 0.05). The 5‑year overall and cause-specific survival rates in the whole cohort were 92 and 96%, respectively, with no significant differences between treatment groups. Anterior commissure involvement was neither a prognostic nor a predictive factor. The incidence of secondary malignancies was not significantly different between patients treated with and without RT (22 vs. 9% at 10 years, respectively, p = 0.18). CONCLUSION: Despite a possible selection bias, our series demonstrates improved RFS with RT over surgery in stage I glottic SCC.
BACKGROUND: The optimal treatment strategy for stage I-II glottic squamous cell carcinoma (SCC) is not well-defined. This study analyzed treatment results and prognostic factors. PATIENTS AND METHODS: This is a single-institution retrospective analysis of 244 patients with T1-2 glottic SCC who underwent normofractionated radiotherapy (RT) and/or surgery between 1990 and 2013. The primary endpoint was relapse-free survival (RFS). RESULTS: Median age was 65 years (range: 36-92 years), the majority (82%) having stage I disease. Definitive RT was used in 82% (median dose: 68 Gy, 2 Gy per fraction). Median follow-up was 59 months. The 5‑year RFS rates were 83 and 75% (p = 0.05) for stage I and 62 and 50% (p = 0.47) for stage II in the RT and surgery groups, respectively. Multivariate analyses indicate T1 vs. T2 and RT vs. surgery as independent prognostic factors for RFS, with hazard ratios of 0.38 (95% confidence interval, CI: 0.21-0.72) and 0.53 (95% CI: 0.30-0.99), respectively (p < 0.05). The 5‑year overall and cause-specific survival rates in the whole cohort were 92 and 96%, respectively, with no significant differences between treatment groups. Anterior commissure involvement was neither a prognostic nor a predictive factor. The incidence of secondary malignancies was not significantly different between patients treated with and without RT (22 vs. 9% at 10 years, respectively, p = 0.18). CONCLUSION: Despite a possible selection bias, our series demonstrates improved RFS with RT over surgery in stage I glottic SCC.
Authors: J S Cooper; T F Pajak; P Rubin; L Tupchong; L W Brady; S A Leibel; G E Laramore; V A Marcial; L W Davis; J D Cox Journal: Int J Radiat Oncol Biol Phys Date: 1989-09 Impact factor: 7.038
Authors: G Marshak; B Brenner; J Shvero; J Shapira; D Ophir; I Hochman; G Marshak; A Sulkes; E Rakowsky Journal: Int J Radiat Oncol Biol Phys Date: 1999-03-15 Impact factor: 7.038
Authors: Bhishamjit S Chera; Robert J Amdur; Christopher G Morris; William M Mendenhall Journal: Int J Radiat Oncol Biol Phys Date: 2009-11-26 Impact factor: 7.038
Authors: Abrahim Al-Mamgani; Stefan L S Kwa; Lisa Tans; Michael Moring; Dennie Fransen; Robert Mehilal; Gerda M Verduijn; Rob J Baatenburg de Jong; Ben J M Heijmen; Peter C Levendag Journal: Int J Radiat Oncol Biol Phys Date: 2015-06-14 Impact factor: 7.038
Authors: Felix Zwicker; Corinna Kirchner; Peter E Huber; Jürgen Debus; Hansjörg Zwicker; Rudolf Klepper Journal: Sci Rep Date: 2019-03-28 Impact factor: 4.379
Authors: Olgun Elicin; Ekin Ermiş; Christoph Oehler; Daniel M Aebersold; Francesca Caparrotti; Frank Zimmermann; Gabriela Studer; Guido Henke; Lukas Adam; Lukas Anschuetz; Mahmut Ozsahin; Matthias Guckenberger; Mohamed Shelan; Nuri Kaydıhan; Oliver Riesterer; Robin J D Prestwich; Thierry Spielmann; Roland Giger; Mehmet Şen Journal: Front Oncol Date: 2019-09-20 Impact factor: 6.244